Celiac Drugs Market- Overview

The global celiac drugs market is present worth USD 703.54 million and is poised to amplify with a CAGR of 16.95% over 2023-2033, thereby amassing a valuation of USD 2462.1 million by end of the assessment timeframe. Celiac disease is referred to as a type of autoimmune disorder which gets trigged by the consumption of gluten based products. The ailment primarily causes inflammation which ends up damaging the lining of the small intestine. The disease also prevents the body from absorbing vital nutrients. People affected with celiac disorder face symptoms such as diarrhea, fatigue, bloating, anemia, wind, and osteoporosis.

Report Scope

The growing pervasiveness of celiac disease, increasing healthcare expenditure, and rising R&D investments in the field are primarily augmenting the outlook of this marketplace. Furthermore, rising focus of pharmaceutical and healthcare research bodies to develop efficient drugs in the field is creating lucrative opportunities for the industry vertical to prosper.

Also, surging health cognizance of the masses, booming biopharmaceutical sector, and increasing geriatric base across the globe are adding momentum to the progression of this business sphere. Moreover, increasing consumption of gluten based food and unavailability of effective drugs for the disease is paving a way for the industry to amass significant gains.

On the contrary, significant regulatory standards pertaining to drug approvals, coupled with rising concerns regarding the side effects of celiac drugs are hindering the remuneration scope of this marketplace.

Celiac Drugs Market- Key trends

Extensive R&D activities in the field to bolster industry growth

There has been a steep rise in the number of R&D activities pertaining to the development of efficient drugs to treat celiac disorder. The related bodies or organizations are working tirelessly to get a breakthrough in this field. Although, as of now there is not specific drugs solely made to treat this disorder, but some biological therapies and immunosuppresants have been developed as an option to cure celiac disorder. This in turn is stimulating the overall dynamics of this marketplace.

Growing consumption of gluten-based products is aiding market expansion

A wide array of consumables including cereals, breads, pasta, baked goods, soup, crackers, and many grain forms contain gluten. Most of the listed edibles are a part of our regular diet which in turn increases our gluten intake on a daily basis. It is a fact that there is no approved diagnostic procedure to determine the presence of the disease. Therefore, many cases go undiagnosed until the symptoms reach an ultimate level. These factors are augmenting the outlook of this business sphere.

Celiac Drugs Market- Segmental Assessment

Celiac disease is an autoimmune disorder caused by the ingestion of gluten, a protein found in wheat, barley, and rye. The current treatment for celiac disease is a strict gluten-free diet, which can be difficult to maintain and can have a significant impact on patients' quality of life.

There is currently no cure for celiac disease, and the development of new treatments, including biological drugs, is an area of active research. Biological drugs are a type of therapy that targets specific molecules or cells involved in the immune response, and have the potential to offer more effective and targeted treatment options for celiac disease.

Several biological drugs are being developed for the treatment of celiac disease, including monoclonal antibodies that target the immune cells involved in the inflammatory response triggered by gluten ingestion. These drugs have shown promising results in clinical trials, with some studies suggesting that they can reduce inflammation and improve symptoms in patients with celiac disease.

The demand for biological drugs for celiac disease is driven by the need for more effective and targeted treatment options that can improve patient outcomes and quality of life. The prevalence of celiac disease is increasing worldwide, and there is a growing need for new therapies that can address the unmet medical needs of patients with this condition.

Overall, the demand for biological drugs for celiac disease is expected to continue to grow in the coming years, driven by the increasing prevalence of the disease, the need for more effective treatments, and the ongoing research and development efforts in this area.

Celiac Drugs Market-Geographical Landscape

The primary regions constituting the geographical ambit of this business sphere are North America, Middle East & Africa, Europe, Asia Pacific, and Latin America. Among these, Asia Pacific is projected to capture a substantial revenue share over the forecast period of 2022-2030. This is attributable to the increasing geriatric population base, rising gluten consumption, and surging healthcare expenditure.

Germany is one of the largest markets for celiac disease drugs in Europe. The demand for celiac drugs in Germany is driven by various factors.

The prevalence of celiac disease in Germany is relatively high, with an estimated 1% of the population affected. This has led to a significant burden on the healthcare system and a growing need for effective and targeted treatments.

The current standard of care for celiac disease in Germany is a strict gluten-free diet, which can be difficult to maintain and may not be effective for all patients. As a result, there is a growing interest in the development of new treatments, including biological drugs, that can offer more effective and targeted therapy options.

Several clinical trials of biological drugs for celiac disease are currently underway in Germany, including trials of monoclonal antibodies that target the immune cells involved in the inflammatory response triggered by gluten ingestion. These drugs have shown promising results in early studies and may offer a new approach to the treatment of celiac disease.

The demand for celiac drugs in Germany is also driven by the country's strong healthcare infrastructure, which supports the development and adoption of innovative therapies. Germany has a well-established regulatory framework for drug development and approval, as well as a robust healthcare reimbursement system that covers a wide range of therapies.

Overall, the demand for celiac drugs in Germany is expected to continue to grow in the coming years, driven by the increasing prevalence of the disease, the need for more effective treatments, and the ongoing research and development efforts in this area.

Celiac Drugs Market-Competitive Intelligence

The prominent players characterizing the competitive terrain of this industry vertical are F. Hoffmann-La Roche, Merck & Co., Inc., Johnson & Johnson, BiolineRx Ltd., Pfizer Inc., Innovate Biopharmaceuticals, ImmusanT, Inc., Novartis AG, Bristol-Myers Squibb Company, and Immunomedics, Inc.

Notably, in August 2019, Innovate Biopharmaceuticals, Inc. announced the enrollment of the first patient in its Phase III clinical trial of a potential celiac disease drug named CeD LA 3001.

Why to buy this Report?

Market research: The report provides valuable insights into market trends, growth opportunities, and competitive landscapes. By reading a technology report, businesses and investors can gain a better understanding of the market they are operating in or considering entering, and make more informed decisions based on data and analysis.

Competitive analysis: The report reports provide detailed information on competitors' strengths, weaknesses, and strategies, which can help businesses identify potential threats and opportunities in the market.

Innovation: The report provides insights into emerging technologies and trends, which can help businesses stay up-to-date with the latest developments and make informed decisions about where to invest their resources.

Due diligence: The report can be used by investors and acquirers as part of their due diligence process when considering investing in or acquiring a technology company. These reports can provide valuable information on the company's financials, technology, market position, and other key factors.

By Type

• Biological drugs

• Immunosuppresants

• Corticosteroids

By Application

• Classical celiac disease

• Non- classical celiac disease

• Silent celiac disease

By Route of administration

• Topical

• Parenteral

• Oral

• Others

By End User

• Hospitals

• Specialty clinics

• Home healthcare

• Others

By Distribution channel

• Direct tender

• Hospital pharmacy

• Retail pharmacy

• Online pharmacy

• Others

Regions

North America

·         U.S.

·         Canada

·         Mexico

Europe

·         Germany

·         U.K.

·         France

·         Italy

·         Spain

·         Russia

·         Rest of Europe

Asia Pacific

·         China

·         Japan

·         India

·         Australia

·         Korea

·         Rest of Asia pacific

South America

·         Brazil

·         Argentina

·         Colombia

·         Rest of South America

Middle East & Africa

·         UAE

·         Saudi Arabia

·         Egypt

·         Oman

·         Kuwait

·         South Africa

·         Rest of MEA